PDL1 targeting by miR-138-5p amplifies anti-tumor immunity and Jurkat cells survival in non-small cell lung cancer.
A549
Calu6
Cytokine
Jurak
NSCLC
PD-L1/PD-1
miR-138-5p
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 06 2024
12 06 2024
Historique:
received:
19
08
2023
accepted:
13
05
2024
medline:
13
6
2024
pubmed:
13
6
2024
entrez:
12
6
2024
Statut:
epublish
Résumé
Non-small cell lung cancer (NSCLC) has constituted over 80% of the lung cancer population with a poor prognosis. Over the past decade, immunotherapy has been constructed in the enlargement of immune checkpoint inhibitors as a promising approach for NSCLC treatment. Evading the immune system using the PD-1/PD-L1 axis is an intelligent way for cancers, and T cells cannot respond fully and confront cancer. Recently, the miR-138 was reported as a PD-L1 regulator in NSCLC. However, its inhibitory impact on T-cell exhaustion has not been characterized. The present study aims to impair PD-L1 (B7-H1) expression in Adenocarcinoma cell lines using miR-138-5p and determines how it prevents Jurak cell exhaustion. To gain the purpose, first, 18 highly significant dysregulated miRNAs containing hsa-miR-138 and CD274-mRNA network were detected in NSCLC based on bioinformatics analysis. Moreover, our study revealed a high level of miR-138-5p could make significant changes like PDL1 downregulation, proliferation, and mortality rate in A549/Calu6 cells. We also simulate cancer environmental conditions by culturing Jurak cells and NSCLC cell lines under the influence of stimulator cytokines to show how miR-138-5p survives Jurak cells by targeting PD-L1/PD-1pathway.
Identifiants
pubmed: 38866824
doi: 10.1038/s41598-024-62064-5
pii: 10.1038/s41598-024-62064-5
doi:
Substances chimiques
MicroRNAs
0
MIRN138 microRNA, human
0
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13542Informations de copyright
© 2024. The Author(s).
Références
Giaccone, G. & He, Y. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer. In Seminars in Cancer Biology. Academic Press (2023).
Padinharayil, H. et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis. 10(3), 960–989 (2023).
pubmed: 37396553
doi: 10.1016/j.gendis.2022.07.023
Khosravi, G.‐R., et al. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. (2024).
Yan, H. et al. Advancements in technology for characterizing the tumor immune microenvironment. Int. J. Biol. Sci. 20(6), 2151–2167 (2024).
pubmed: 38617534
pmcid: 11008272
doi: 10.7150/ijbs.92525
Liu, R., Li, H.-F. & Li, S. PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy. Cell Insight 3(2), 100146 (2024).
pubmed: 38425643
pmcid: 10901852
doi: 10.1016/j.cellin.2024.100146
Li, H.. The PD-1 and PD-L1 checkpoint and the application of their inhibitors. In Third International Conference on Biological Engineering and Medical Science (ICBioMed2023) vol. 12924 (SPIE, 2024).
Ecker, M. E., et al. Immune-mediated gastritis in a patient with metastatic lung cancer due to therapy with the immune checkpoint inhibitor pembrolizumab–differences and similarities in comparison to “endogenous” autoimmune type A gastritis and a review of literature. Zeitschrift für Gastroenterologie (2023).
Liu, N., et al. Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy. Bioorg. Chem. 106550 (2023).
Chen, X. et al. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: A systematic review and network meta-analysis. Front. Immunol. 15, 1255577 (2024).
pubmed: 38390328
pmcid: 10881808
doi: 10.3389/fimmu.2024.1255577
Javed, S. et al. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: Success and challenges. Front. Immunol. 15, 1383456 (2024).
pubmed: 38660299
pmcid: 11039846
doi: 10.3389/fimmu.2024.1383456
Inthagard, J., Edwards, J. & Roseweir, A. K. Immunotherapy: Enhancing the efficacy of this promising therapeutic in multiple cancers. Clin. Sci. 133(2), 181–193 (2019).
doi: 10.1042/CS20181003
Deng, J. et al. Research progress on the intrinsic non-immune function of PD-L1 in tumors. Oncol. Lett. 25(1), 1–13 (2023).
Chen, J., Jiang, C., Jin, L. & Zhang, X. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 27(3), 409–416 (2016).
pubmed: 26681673
doi: 10.1093/annonc/mdv615
Somboonpatarakun, C. et al. Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer. Int. Immunopharmacol. 129, 111631 (2024).
pubmed: 38359664
doi: 10.1016/j.intimp.2024.111631
Min, V. et al. Metastatic melanoma in young child. J. Pediatr. Hematol./Oncol. 45(8), 461–462 (2023).
pubmed: 37027236
doi: 10.1097/MPH.0000000000002663
Abiko, K. et al. Dynamic host immunity and PD-L1/PD-1 blockade efficacy: Developments after “IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer”. Br. J. Cancer 128(3), 461–467 (2023).
pubmed: 36068276
doi: 10.1038/s41416-022-01960-x
Hirayama, A. et al. Regulation of PD-L1 expression in non–small cell lung cancer by interleukin-1β. Front. Immunol. 14, 1192861 (2023).
pubmed: 37441079
pmcid: 10333574
doi: 10.3389/fimmu.2023.1192861
Skorin, R. M. et al. Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining. Actas Urológicas Españolas (English Edition) 47(5), 271–278 (2023).
doi: 10.1016/j.acuroe.2022.12.005
Liu, P. et al. IFIT3 accelerates the progression of head and neck squamous cell carcinoma by targeting PD-L1 to activate PI3K/AKT signaling pathway. World J. Surg. Oncol. 22(1), 34 (2024).
pubmed: 38273364
pmcid: 10809513
doi: 10.1186/s12957-023-03274-5
Deng, X. et al. Upregulation of MTHFD2 is associated with PD-L1 activation in bladder cancer via the PI3K/AKT pathway. Int. J. Mol. Med. 51(2), 1–15 (2023).
Song, K. Y. et al. MET receptor tyrosine kinase inhibition reduces interferon-gamma (IFN-γ)-stimulated PD-L1 expression through the STAT3 pathway in melanoma cells. Cancers 15(13), 3408 (2023).
pubmed: 37444518
pmcid: 10340457
doi: 10.3390/cancers15133408
Larsen, T. V. et al. PD-L1 and PD-L2 immune checkpoint protein induction by type III interferon in non-small cell lung cancer cells. Immunobiology 228(3), 152389 (2023).
pubmed: 37146414
doi: 10.1016/j.imbio.2023.152389
Huang, Y. et al. CD8+ T cell exhaustion in anti-tumour immunity: The new insights for cancer immunotherapy. Immunology 168(1), 30–48 (2023).
pubmed: 36190809
doi: 10.1111/imm.13588
Tamaddon, M. et al. Involved microRNAs in alternative polyadenylation intervene in breast cancer via regulation of cleavage factor “CFIm25”. Sci. Rep. 10(1), 1–11 (2020).
doi: 10.1038/s41598-020-68406-3
Shang, R. et al. microRNAs in action: Biogenesis, function and regulation. Nat. Rev. Genet. 24(12), 816–833 (2023).
pubmed: 37380761
pmcid: 11087887
doi: 10.1038/s41576-023-00611-y
Huang, F. et al. Analysis and prediction of protein stability based on interaction network, gene ontology, and KEGG pathway enrichment scores. Biochim. Biophys. Acta (BBA) Proteins Proteom. 171(3), 140889 (2023).
doi: 10.1016/j.bbapap.2023.140889
Zhu, W. et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS ONE 11(4), e0153046 (2016).
pubmed: 27093275
pmcid: 4836744
doi: 10.1371/journal.pone.0153046
Davenport, M. L. et al. miR-31 displays subtype specificity in lung cancer. Cancer Res. 81(8), 1942–1953 (2021).
pubmed: 33558335
pmcid: 8137562
doi: 10.1158/0008-5472.CAN-20-2769
Wang, B., Sun, L., Li, J. & Jiang, R. miR-577 suppresses cell proliferation and epithelial-mesenchymal transition by regulating the WNT2B mediated Wnt/β-catenin pathway in non-small cell lung cancer. Mol. Med. Rep. 18(3), 2753–2761 (2018).
pubmed: 30015869
pmcid: 6102634
Zhang, X.-B., et al. MiR-210-3p enhances intermittent hypoxia-induced tumor progression via inhibition of E2F3. Sleep Breath. 1–11 (2023).
Wu, C.-Y. et al. Ugonin P inhibits lung cancer motility by suppressing DPP-4 expression via promoting the synthesis of miR-130b-5p. Biomed. Pharmacother. 167, 115483 (2023).
pubmed: 37703658
doi: 10.1016/j.biopha.2023.115483
Danielson, L. S. et al. MiR-130b modulates the invasive, migratory, and metastatic behavior of leiomyosarcoma. PLoS ONE 18(1), e0278844 (2023).
pubmed: 36701370
pmcid: 9879492
doi: 10.1371/journal.pone.0278844
Wang, L., Lei, Wu. & Pang, J. Long noncoding RNA PSMA3-AS1 functions as a microRNA-409-3p sponge to promote the progression of non-small cell lung carcinoma by targeting spindlin 1. Oncol. Rep. 44(4), 1550–1560 (2020).
pubmed: 32945481
pmcid: 7448465
Al-Hussaniy, H. A. The effect of MicroRNA-409-3p for treatment and response to tumor proliferation of lung cancer cell lines (in vitro). Asian Pac. J. Cancer Prev. APJCP 23(9), 3151 (2022).
pubmed: 36172678
doi: 10.31557/APJCP.2022.23.9.3151
Chang, J.-H. et al. BRF2 is mediated by microRNA-409–3p and promotes invasion and metastasis of HCC through the Wnt/β-catenin pathway. Cancer Cell Int. 23(1), 46 (2023).
pubmed: 36927769
pmcid: 10018885
doi: 10.1186/s12935-023-02893-y
Jiao, D. et al. miR-1/133a and miR-206/133b clusters overcome HGF induced gefitinib resistance in non-small cell lung cancers with EGFR sensitive mutations. J. Drug Target. 29(10), 1111–1117 (2021).
pubmed: 33955799
doi: 10.1080/1061186X.2021.1927054
Zhang, Q. et al. BAP31-mediated miR-206/133b cluster promotes transendothelial migration and metastasis of colorectal cancer. Int. J. Mol. Sci. 24(23), 16740 (2023).
pubmed: 38069061
pmcid: 10706076
doi: 10.3390/ijms242316740
Zhao, C., et al. Circular RNA circRANGAP1/miR-512-5p/SOD2 axis regulates cell proliferation and migration in non-small cell lung cancer (NSCLC). Mol. Biotechnol. 1–10 (2023).
Lu, X. et al. Piperlongumine inhibits the growth of non-small cell lung cancer cells via the miR-34b-3p/TGFBR1 pathway. BMC Complement. Med. Ther. 21, 1–10 (2021).
doi: 10.1186/s12906-020-03123-y
Li, Z. et al. [Retracted] miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9. Oncol. Rep. 47(2), 1–1 (2022).
Singh, S., et al. Emerging role of tumor suppressing microRNAs as therapeutics in managing Non-small cell lung cancer. Pathol.-Res. Pract. 155222 (2024).
Wang, L. et al. CircABCC1 promotes the development of glioma by sponging miR-591 and modulating high-mobility group A2. Ann. N. Y. Acad. Sci. 1511(1), 107–118 (2022).
pubmed: 35000195
doi: 10.1111/nyas.14717
Fan, G. et al. Long non-coding RNA HCG11 sponging miR-522-3p inhibits the tumorigenesis of non-small cell lung cancer by upregulating SOCS5. Thorac. Cancer 11(10), 2877–2886 (2020).
pubmed: 32844573
pmcid: 7529553
doi: 10.1111/1759-7714.13624
Zor, D. S. et al. Plasma levels of kynurenine, soluble OX40 and Mir-138-5p are associated with tumor-infiltrating lymphocytes in colorectal cancer: An exploratory study. Anticancer Res. 43(7), 3281–3288 (2023).
pubmed: 37351968
doi: 10.21873/anticanres.16503
Cheng, D. et al. Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation. Med. Oncol. 40(9), 254 (2023).
pubmed: 37505345
doi: 10.1007/s12032-023-02125-3
Wang, Z., Wang, B. & Wang, K. Targeting TRIM9 by miR-218-5p restricts cell proliferation and epithelial-mesenchymal transition in non-small cell lung cancer. Ann. Clin. Lab. Sci. 53(1), 106–115 (2023).
pubmed: 36889762
Kong, T. et al. CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers. Cancer Res. 80(3), 444–457 (2020).
pubmed: 31722999
doi: 10.1158/0008-5472.CAN-19-1108
Ho, P., Melms, J. C., Rogava, M., Frangieh, C. J., Shah, S. B., Walsh, Z., et al. The CD58: CD2 Axis is Co-regulated with PD-L1 via CMTM6 and governs Anti-tumor Immunity. bioRxiv. 2022:2022.03.21.485049.
Wang, Y. et al. EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells. Cell Cycle 17(12), 1457–1470 (2018).
pubmed: 29954240
pmcid: 6132955
doi: 10.1080/15384101.2018.1489177
Chan, L. C. et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J. Clin. .ation 129(8), 3324–3338 (2019).
Huseni, M. A. et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep. Med. 4(1), 100878 (2023).
pubmed: 36599350
pmcid: 9873827
doi: 10.1016/j.xcrm.2022.100878
Chen, S. et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J. Immunother. Cancer 7, 1–12 (2019).
doi: 10.1186/s40425-019-0770-2
Singh, L., Singh, M. K., Rizvi, M. A. & Kashyap, S. 16P PD-1/PD-L1 expression in uveal melanoma: Prognostic significance with tumour-infiltrating lymphocytes and clinicopathological parameters. Ann. Oncol. 31, S1422 (2020).
doi: 10.1016/j.annonc.2020.10.501
Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8(328), 328rv4-328rv4 (2016).
doi: 10.1126/scitranslmed.aad7118
Zhang, Q. et al. Aerosolized miR-138–5p and miR-200c targets PD-L1 for lung cancer prevention. Front. Immunol. 14, 1166951 (2023).
pubmed: 37520581
pmcid: 10372486
doi: 10.3389/fimmu.2023.1166951
Zhang, W., Liao, K. & Liu, D. MiR-138-5p inhibits the proliferation of gastric cancer cells by targeting DEK [Retraction]. Cancer Manag. Res. 15, 487–488 (2023).
doi: 10.2147/CMAR.S424973
Gong, J., Tang, Z., Yu, Z., Deng, Z., Liu, Y., Ren, N. & He, Z. miR-138-5p Inhibits the Growth and Invasion of Glioma Cells by Regulating WEE1. Anal. Cell. Pathol. (2022).
Wu, J. et al. MiR-138-5p suppresses the progression of lung cancer by targeting SNIP1. Thoracic Cancer 14(6), 612–623 (2023).
pubmed: 36597175
pmcid: 9968603
doi: 10.1111/1759-7714.14791
Zhu, J. et al. miR-138-5p targets MCU to inhibit mitochondrial biogenesis and colorectal cancer growth. J. Cell. Mol. Med. 27(15), 2112–2122 (2023).
pubmed: 37264759
pmcid: 10399525
doi: 10.1111/jcmm.17798
Li, J. et al. Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo. Sci. Rep. 14(1), 2348 (2024).
pubmed: 38287075
pmcid: 10824707
doi: 10.1038/s41598-024-52896-6
Zou, Y. et al. Discovery of tryptanthrin and its derivatives and its activities against NSCLC in vitro via both apoptosis and autophagy pathways. Int. J. Mol. Sci. 24(2), 1450 (2023).
pubmed: 36674964
pmcid: 9861433
doi: 10.3390/ijms24021450
Barclay, J., Creswell, J. & León, J. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway. Archivos espanoles de urologia 71(4), 393–399 (2018).
pubmed: 29745928
De Sousa, L. A. et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Sci. Rep. 9(1), 11472 (2019).
doi: 10.1038/s41598-019-47910-1
Bassanelli, M. et al. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. Anticancer Res. 38(7), 3789–3796 (2018).
pubmed: 29970498
doi: 10.21873/anticanres.12662
Hoekstra, M. E., Vijver, S. V. & Schumacher, T. N. Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines. Curr. Opin. Immunol. 69, 65–71 (2021).
pubmed: 33862306
pmcid: 7610766
doi: 10.1016/j.coi.2021.03.016
Cheng, C. C. et al. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. Mol. Carcinog. 57(11), 1588–1598 (2018).
pubmed: 30035369
doi: 10.1002/mc.22881
Zhang, X. et al. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int. J. Clin. Oncol. 22, 1026–1033 (2017).
pubmed: 28748356
doi: 10.1007/s10147-017-1161-7
Roy Barman, S. & Jhunjhunwala, S. Electrical stimulation for immunomodulation. ACS Omega 9(1), 52–66 (2023).
pubmed: 38222551
pmcid: 10785302
doi: 10.1021/acsomega.3c06696
Carroll, K. L. et al. Differential expression of immune checkpoint molecules on CD8+ T cells specific for immunodominant and subdominant herpes simplex virus 1 epitopes. J. Virol. 94(2), 10–1128 (2020).
doi: 10.1128/JVI.01132-19
Jia, Y. et al. HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma. J. Transl. Med. 22(1), 272 (2024).
pubmed: 38475878
pmcid: 10936085
doi: 10.1186/s12967-024-05069-y
Kaewthawee, N. & Brimson, S. The effects of ursolic acid on cytokine production via the MAPK pathways in leukemic T-cells. EXCLI J. 12, 102 (2013).
pubmed: 26417220
pmcid: 4531796
Khoroshevskyi, O. et al. GEOfetch: A command-line tool for downloading data and standardized metadata from GEO and SRA. Bioinformatics 39(3), btad069 (2023).
pubmed: 36857584
pmcid: 9982356
doi: 10.1093/bioinformatics/btad069
Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43(7), e47-e (2015).
doi: 10.1093/nar/gkv007
Guo, Y., Xiao, Y. and Li, L. Identifying differentially expressed genes in RNA sequencing data with small labelled samples. In IEEE/ACM Transactions on Computational Biology and Bioinformatics (2024).
Gysi, D. M. et al. wTO: An R package for computing weighted topological overlap and a consensus network with integrated visualization tool. BMC Bioinform. 19, 1–16 (2018).
doi: 10.1186/s12859-018-2351-7
Szklarczyk, D. et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47(D1), D607–D613 (2019).
pubmed: 30476243
doi: 10.1093/nar/gky1131